Sustained Virologic Response
"Sustained Virologic Response" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The continuous, long-term suppression of VIRAL LOAD, generally to undetectable levels, as the result of treatment with ANTIVIRAL AGENTS.
| Descriptor ID |
D000072230
|
| MeSH Number(s) |
E01.789.800.570 N04.761.559.590.800.665 N05.715.360.575.575.800.665
|
| Concept/Terms |
Sustained Virologic Response- Sustained Virologic Response
- Response, Sustained Virologic
- Sustained Virologic Responses
- Virologic Response, Sustained
- Sustained Viral Suppression
- Suppression, Sustained Viral
- Sustained Viral Suppressions
|
Below are MeSH descriptors whose meaning is more general than "Sustained Virologic Response".
Below are MeSH descriptors whose meaning is more specific than "Sustained Virologic Response".
This graph shows the total number of publications written about "Sustained Virologic Response" by people in this website by year, and whether "Sustained Virologic Response" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 4 | 4 |
| 2017 | 1 | 3 | 4 |
| 2018 | 0 | 5 | 5 |
| 2019 | 1 | 4 | 5 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 4 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sustained Virologic Response" by people in Profiles.
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2024 01; 22(1):72-80.e4.
-
Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response. Clin Transplant. 2023 10; 37(10):e15050.
-
Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol. 2023 09 01; 118(9):1609-1617.
-
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance. Ann Hepatol. 2023 Mar-Apr; 28(2):100899.
-
High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus. Eur J Gastroenterol Hepatol. 2022 10 01; 34(10):1098-1101.
-
Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in hepatitis C virus monoinfected cancer patients: a prospective observational study. Diagn Microbiol Infect Dis. 2022 Jul; 103(3):115719.
-
Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol. 2022 Jan 07; 28(1):96-107.
-
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology. 2021 12; 74(6):2952-2964.
-
HIV-Adapted Group Prenatal Care: Assessing Viral Suppression and Postpartum Retention in Care. AIDS Patient Care STDS. 2021 02; 35(2):39-46.